Tech Transfer Roundup: Trio Of Deals Bolster Spherix’s Cancer Strategy
The New York biotech announces option deals with two universities, asset license from CBM BioPharma. Bayer inks research collaborations with Japan’s RiKen and with a pair of Boston research hospitals.
You may also be interested in...
With the planned $487m acquisition of sensorineural-focused Akouos, Lilly makes its second gene therapy M&A play in two years, on top of partnering/financing activity in the space.
MD Anderson teams with Eisbach on precision oncology and with Yingli on a five-year translational research effort. Moffitt inks tie-ups with Dyve and Turnstone.
RiKen gets $9.3m up front plus potential milestones and royalties for use of its aAVC technology, while retaining research rights to the platform. JW Pharmaceutical acquires Vietnam’s Euvipharm.